Literature DB >> 21472824

Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids.

Míriam Mañosa1, Eduard Cabré, Esther Garcia-Planella, Isabel Bernal, Jordi Gordillo, Maria Esteve, Yamile Zabana, Miquel Angel Gassull, Eugeni Domènech.   

Abstract

BACKGROUND: Corticosteroids are the treatment of choice for moderate-to-severe active ulcerative colitis (UC) but up to 30%-40% of patients fail to respond. It has been reported that early clinical-biological parameters may identify those patients at high risk of colectomy. The aim was to identify predictors of rapid response to systemic steroids in moderate-to-severe attacks of UC.
METHODS: Consecutive patients treated with prednisone 1 mg/kg/day for moderate-to-severe attacks of UC were prospectively included. Clinical and biological parameters at 3 and 7 days after starting steroids were recorded. Response was defined as mild or inactive UC activity at day 7 (as assessed by the Montreal Classification of severity) together with no need for rescue therapies (cyclosporin, infliximab, or colectomy). A logistic regression analysis was performed to identify those independent predictors of response. In addition, a decision-tree analysis was also performed.
RESULTS: Sixty-eight percent of patients (64 out of 94) responded to steroids. In the univariate analysis the number of bowel movements, rectal bleeding, platelet count, and C-reactive protein (CRP) levels at day 3 were associated with response at day 7, but only rectal bleeding was found to be an independent predictor in the logistic regression analysis. Conversely, the classification and regression tree (CART) model included these four variables. The decision-tree model showed a higher sensitivity in predicting a rapid response to steroids than the logistic regression one.
CONCLUSIONS: Rapid response to steroids in active UC attacks can be predicted after 3 days of treatment by simple clinical and biological parameters. A decision-tree model for early introduction of rescue therapies is provided.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21472824     DOI: 10.1002/ibd.21634

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  3 in total

Review 1.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

2.  Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis.

Authors:  Joseph D Feuerstein; Mona Akbari; Elliot B Tapper; Adam S Cheifetz
Journal:  Ann Gastroenterol       Date:  2016-04-07

Review 3.  Medical Therapy of Active Ulcerative Colitis.

Authors:  Martin Bürger; Carsten Schmidt; Niels Teich; Andreas Stallmach
Journal:  Viszeralmedizin       Date:  2015-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.